Neurotech’s Cannabinoid Drug Reports Positive Results From Key Study

PK study shows further promise for Neurotech paediatric CBDA drug

The first human pharmacokinetics study of Neurotech International’s broad-spectrum cannabinoid treatment, NTI164, has shown positive results […] The post PK study shows further promise for Neurotech paediatric CBDA drug appeared first on Cannabiz.

Neurotech’s cannabinoid drug reports positive results from key study

Neurotech reports positive results from first-in-human pharmacokinetic study of broad-spectrum cannabinoid drug NTI164 Study confirms fast, predictable absorption of NTI164, with CBDA as main cannabinoid Minimal THC exposure confirms NTI164’s non-intoxicating profile, supporting suitability for paediatric use   Special Report: Neurotech has received positive results from its first-in-human pharmacokinetic (PK) study evaluating its proprietary br…